Neurocrine Biosciences | NBIX - Operating Expenses


Neurocrine Biosciences reported $599.9M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Prothena USD 25.29M 1.94M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Repligen USD 174.27M 3.67M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xoma USD 22.84M 1.67M Sep/2024